deltatrials

Abramson Cancer Center at Penn Medicine Clinical Trials

Sponsors / Abramson Cancer Center at Penn Medicine

ClinicalTrials.gov lists 424 trials for which Abramson Cancer Center at Penn Medicine is named as lead sponsor. The portfolio currently includes 72 recruiting studies, 47 active non-recruiting studies, and 240 completed studies. 46 trials in this portfolio were terminated or withdrawn before completion. The most common reasons cited for termination include slow or insufficient recruitment, safety concerns. Cumulative planned enrollment across all listed trials is 482,204 participants. These counts reflect the current state of the public ClinicalTrials.gov registry.

424
Total Trials
72
Recruiting
47
Other Active
240
Completed
46
Terminated / Withdrawn
482,204
Total Enrollment

Termination reasons: Recruitment43% · Other41% · Safety7% · Efficacy4% · PI/or_Site2% · Funding2%

Recent Terminations

  • NCT05790460 Phase NA Stopped Nov 2024
    Non-small Cell Lung Cancer
    "Insufficient accrual"
  • NCT03492164 Phase EARLY_PHASE1 Stopped Jun 2024
    Pancreatic Cancer
    "Early analysis of images after 6 patients showed no activity of the radiotracer in this patient population."
  • NCT04873895 Phase PHASE1 Stopped Apr 2024
    Colorectal Neoplasms Malignant
    "failure to accrue"
  • NCT04429321 Phase PHASE1 Stopped Jan 2024
    Renal Cell Carcinoma
    "failure to accrue"
  • NCT03781960 Phase PHASE2 Stopped Apr 2022
    Hepatocellular Carcinoma
    "Safety letter from sponsor"
  • NCT03495713 Phase PHASE2 Stopped Apr 2022
    Hodgkin Lymphoma
    "Covid-19"
  • NCT03519308 Phase EARLY_PHASE1 Stopped Apr 2022
    Pancreatic Cancer
    "The accrual goal could not be met and the drug manufacturer pulled support"
  • NCT03693846 Phase PHASE2 Stopped Mar 2021
    Mucinous Adenocarcinoma of the Colon
    "Terminated due to slow enrollment and lack of efficacy"
  • NCT03483883 Phase PHASE1 Stopped Feb 2021
    Metastatic sRCC
    "The study was terminated due to protracted accrual and limited patient engagement in the setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features."
  • NCT03573986 Phase PHASE1 Stopped Jan 2020
    Recurrent Glioblastoma
    "Lack of enrollment"

Active Trials (47 total)

See all 47 active trials

Top Conditions

Breast cancer (48) Cancer (19) Lung cancer (12) Prostate cancer (9) Colorectal cancer (8) Pancreatic cancer (8) Head and neck cancer (7) Cervical cancer (6) Hepatocellular carcinoma (6) Non-small cell lung cancer (6)

Top Locations

Philadelphia, United States (409) Lancaster, United States (14) Baltimore, United States (6) Boston, United States (6) Chicago, United States (6) New York, United States (6) Birmingham, United States (5) Buffalo, United States (5) Chapel Hill, United States (5) Houston, United States (5)